FK506 Antibody (FK1) [FITC]

Product Discontinued

FK506 Antibody (FK1) [FITC] Summary

• Immunogen: FK-506-BSA conjugate
• Specificity: NB100-62571 detects FK-506, a macrolide with similar but more potent immunosuppressant activity than cyclosporine. It is a 23-membered lactone produced by the bacteria Streptomyces tsukubaensis. FK-506 inhibits signal transduction and interleukin-2 transcription in CD4+ T helper lymphocytes, and is mainly used after allogenic organ transplantation to reduce organ rejection. Side effects of FK-506 treatment include nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension.
• Isotype: IgM
• Clonality: Monoclonal
• Host: Mouse
• Purity: IgM purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000

Reactivity Notes

Reacts with Chemical.

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: 50 mM Tris/HCl, (pH 8.0) 150 mM NaCl
• Preservative: 0.05% Sodium Azide
• Purity: IgM purified

Alternate Names for FK506 Antibody (FK1) [FITC]

• C44H69NO12;FK-506;Fujimycin;Tacrolimus

Background

FK506 antigen is a novel macrolide with similar but more potent immunosuppressant activity than cyclosporine. FK506 is used for primary or rescue immunosuppression in patients after solid organ transplantation. Clinically relevant FK506 side effects are nephrotoxicity, neurotoxicity, diabetes mellitus and hypertension. Most of these side effects are more closely related to FK 506 blood levels than dosage; therefore therapeutic drug monitoring (TDM) of FK506 levels is a prerequisite for therapy. Whole blood is the matrix of choice for FK506 TDM. The whole blood target level range aimed for in clinical practice is between 3.0 and 20.0 ng/ml and depends on the patient's liver function, the type of organ transplanted and the time after transplantation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.